

PEDIATRIC HIGH GRADE GLIOMA RESOURCES FROM THE CHILDREN'S BRAIN TUMOR TISSUE CONSORTIUM (CBTTC) AND PEDIATRIC BRAIN TUMOR ATLAS (PBTA)

Heba Ijaz^{1*}, Mateusz Koptyra^{2,3*}, Krutika S. Gaonkar⁴, Jo Lynne Rokita², Valerie P. Baubet^{2,3}, Lamiya Tauhid^{2,3}, Yankun Zhu², Miguel Brown², Gonzalo Lopez¹, Bo Zhang², Sharon J. Diskin^{1,4,7}, Zalman Vaksman¹, Children's Brain Tumor Tissue Consortium, Jennifer L. Mason^{2,3}, Elizabeth Appert^{2,3}, Jena Lilly^{2,3}, Rishi Lulla⁸, Thomas De Raedt^{6,7}, Allison P. Heath², Alex Felmeister⁴, Pichai Raman⁴, Javad Nazarian^{3,10}, Maria Rita Santi^{6,7}, Phillip B. Storm^{2,3,5,7}, Adam Resnick^{2,3,5}, Angela J. Waanders^{2,3,10} and Kristina A. Cole^{1, 7}

Affiliations:

¹Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia

²The Center for Data Driven Discovery in Biomedicine (D³b), Children's Hospital of Philadelphia

³The Children's Brain Tumor Tissue Consortium (CBTTC), Operations Center at the Children's Hospital of Philadelphia

⁴Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia

⁵Department of Neurosurgery, Children's Hospital of Philadelphia

⁶Department of Pathology, Children's Hospital of Philadelphia

⁷The Perelman School of Medicine, University of Pennsylvania

⁸Division of Hematology/Oncology, Hasbro Children's Hospital, Department of Pediatrics, The Warren Alpert School of Brown University

⁹Children's Research Institute, Children's National Medical Center, School of Medicine and Health Sciences, George Washington University, Washington, DC

¹⁰Division of Hematology, Oncology, and Stem Cell Transplant, Ann & Robert H Lurie Children's Hospital of Chicago, Department of Pediatrics, Feinberg School of Medicine Northwestern University, Chicago, IL

Running title: CBTTC Pediatric high grade glioma resources

Corresponding Author:

Kristina A. Cole, M.D., Ph.D.

Division of Oncology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Address: 3054 Colket Translational Research Building, Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA 19104

Email: colek@email.chop.edu

Phone: 267-426-2285

Fax: 267-426-0685

*Contributed equally to this work

Conflict of Interest: none

Authorship:

Conception or design of the work: HI, MK, PR, SD, AR, AW, KC

Acquisition, analysis, or interpretation of data for the work: HI, MK, VB, LY, KG, JLR, GG, PR, YZ, MB, BZ, JM, JL, RL, AF, JN, MS, PS, AR, AW, KC

Manuscript preparation and review: all authors

manuscript word count: total (5853), abstract (250), text (5483), references (710), and table and figure legends (664)

ABSTRACT

Background: Pediatric high grade glioma (pHGG) remains a fatal disease. Increased access to richly annotated biospecimens and patient derived tumor models will accelerate pHGG research and support translation of research discoveries. This work describes the pediatric high grade glioma set of the Children’s Brain Tumor Tissue Consortium (CBTTC) from the first release (October 2018) of the Pediatric Brain Tumor Atlas (PBTA).

Methods: pHGG tumors with associated clinical data and imaging were prospectively collected through the CBTTC and analyzed as the Pediatric Brain Tumor Atlas (PBTA) with processed genomic data deposited into PedcBioPortal for broad access and visualization. Matched tumor was cultured to create high grade glioma cell lines analyzed by targeted and WGS and RNA-seq. A tissue microarray (TMA) of primary pHGG tumors was also created.

Results: The pHGG set included 87 collection events (73 patients, 60% at diagnosis, median age of 9 yrs, 55% female, 46% hemispheric). Analysis of somatic mutations and copy number alterations of known glioma genes were of expected distribution (36% *H3.3*, 47% *TP53*, 24% *ATRX* and 7% *BRAF* V600E variants). A pHGG TMA (n=77), includes 36 (53%) patient tumors with matched sequencing. At least one established glioma cell line was generated from 23 patients (32%). Unique reagents include those derived from a *H3.3* G34R glioma and from tumors with mismatch repair deficiency.

Conclusion: The CBTTC and PBTA have created an openly available integrated resource of over 2,000 tumors, including a rich set of pHGG primary tumors, corresponding cell lines and archival fixed tissue to advance translational research for pHGG.

KEY WORDS: pediatric high grade glioma, patient derived cell lines, tumor resource, CBTTC, PBTA, ATRX

IMPORTANCE OF STUDY

High-grade gliomas (HGG) remain the leading cause of cancer death in children. Since molecularly heterogeneous, preclinical studies of pediatric HGG will be most informative if able to compare across groups. Given their relatively rarity, there are few readily available biospecimens and cellular models to inform preclinical laboratory and genomic translational research. Therefore, the aim of this CBTTC study was to highlight the panel of pediatric HGG cases whose primary tumors have undergone extensive genomic analysis, have clinical data, available imaging and additional biospecimens, including tumor, nucleic acids, cell lines and FFPE tissue on a tissue microarray (TMA).

INTRODUCTION

Pediatric high grade glioma is a leading cause of pediatric cancer death, with most children dying of their disease within 2 years of diagnosis. Recent large genomic studies have shown that pHGGs arise along embryonic developmental lineages and are genomically and spatially distinct.^{1 2} Anatomically midline tumors (e.g. thalamic, pontine) often have recurrent mutations in *H3.3* K27M (38% of all non-brainstem pHGG), and have earned the WHO classification of diffuse midline K27M mutant gliomas. In contrast, anatomically hemispheric tumors are more likely to have recurrent mutations in *H3.3* G34R/V, *IDH1* and *SETD2*. Additional recurrent mutations occur in *TP53*, *ATRX* and *BRAF*. Indeed, these discoveries are prompting the development of *H3.3* K27M targeted therapies and improved interpretation of high grade glioma clinical trial results.^{3 4}

In order to advance biological studies and clinical translation of these genomic discoveries in pHGG, it is necessary to 1) increase the availability of pre-clinical models linked to patient biospecimens as well as publicly available pHGG genomic datasets and 2) present the linked genomics data and clinical annotations in a manner that is accessible to the general scientific community. The Children's Brain Tumor Tissue Consortium (CBTTC) is an international multi-institution biorepository that aims to integrate genomic and molecular research with biorepository management. Here we describe the generation and characterization of a highly annotated set of non-brainstem pediatric high grade glioma reagents freely available to the community to accelerate research of this devastating disease.

MATERIALS AND METHODS

General and laboratory methods:

CBTTC biorepository query. The CBTTC (cbttc.org) is a collaborative, multi-institutional research program dedicated to the study of childhood brain tumors. The consortium currently includes 16 institutions worldwide (see Appendix). The CBTTC open source biorepository (<https://eig.research.chop.edu/cbttc/>) is available to member and non-member investigators through a submission request system. A research proposal request for biospecimens and/or data (clinical, imaging, histology slides, genomics) goes through a peer review process to approve specimen distribution and data sharing.⁵ After approval, the specimens are delivered to investigators while CBTTC data is available for viewing and download from the Gabriella Miller Kids First Data Resource Center (KF-DRC,

<https://kidsfirstdrc.org>). Clinical reports can be downloaded as PDFs and Aperio SVS histology images viewed with QuPath.⁶ Pre- and post-operative MRI images and reports are also available for a subset of the CBTTTC subjects.

Processed Genomic Data. Next generation sequencing of over 1200 tumors from the CBTTTC was completed in 2018 and deposited in the KF-DRC, as part of the Pediatric Brain Tumor Atlas (PBTA) as described below. Once approved, data is available for local download, analysis in the cloud-based data sharing platform CAVATICA or visualization of processed data in PedcBioPortal.⁷ For this study, CBTTTC pHGG/PNET tumor sequences from the PBTA release 1 date of 10/30/18 were re-harmonized in 3/2019 and uploaded into PedcBioPortal (<https://pedcbioportal.org>), with proteomic data available for select cases.⁷ Somatic mutations and copy number alterations in known pHGG and mismatch repair genes from PedcBioPortal were included if they were considered likely pathogenic by the OncoKB level of evidence tiers 1-4.⁸

Human Subject Research Protections. All subjects were consented to tissue and data collection through CBTTTC institutional IRB approved protocols. The KF-DRC is recognized as a National Institutes of Health (NIH) trusted partner for data sharing protections.

Identification of pHGG specimens for cell line generation. A search of the CBTTTC biorepository (>3000 unique patients) in November 2017, revealed 37 non-brainstem pHGG tumors that had been stored in freezing media and available for tissue dissociation and cell culture generation as described below. As it is now recognized that up to 30% of tumors previously identified as Primitive Neuroectodermal Tumors (PNETs) are pHGGs,⁹ PNETs were included in the search, but only included if a H3.3 G34R (n=2) or K27M (n=1) mutation was present.

Tissue dissociation and cell culture. All cell lines were generated by the CBTTTC from prospectively collected tumor specimens stored in Recover Cell Culture Freezing media (Gibco, cat. 12648010) and dissociated as described in the Supplementary Methods. Up to three culture conditions were initiated based on the number of cells. For FBS cultures, a minimum density of 3×10^5 cells/ml were plated in DMEM/F-12 medium supplemented with 20% fetal bovine serum (Hyclone, cat. SH30910.03), 1% GlutaMAX (Gibco, cat. 35050061), 100 U/mL penicillin-streptomycin and 0.2% Normocin (Invitrogen, cat. ant-nr-1). The remaining cells were plated in serum-free Neurobasal-A media (Gibco,

10888022) supplemented with 1% GlutaMAX, 1x B-27 supplement minus vitamin A (Gibco, cat. 12587010), 1x N-2 supplement (Gibco, cat. 17502001), 20 ng/ml epidermal growth factor (PeproTech, cat. AF-100-15B), 20 ng/ml basic fibroblast growth factor (PeproTech, cat. 100-18B), 10 ng/ml platelet-derived growth factor AA (100-13A), and 10 ng/ml platelet-derived growth factor BB (PeproTech, cat. 100-14B), 4µg/ml heparin (StemCell, cat. 07980), 100U/mL penicillin-streptomycin and 0.2% Normocin. Serum-free culture conditions included cells plated directly into media (SF) or on an extracellular Geltrex matrix denoted SF-ECM (Life Technologies, cat. A1413302) according to the manufacturer's thin-gel method. Serum-free cells were initiated in culture with a minimum density of 1×10^6 cells/ml. In cases where low cell counts prevented generation of a SF-ECM line at dissociation, established FBS cells were transitioned to the SF-ECM condition by the Cole laboratory staff at the lowest passage possible.

Genomic Methods:

DNA/RNA extraction, library preparation and sequencing. DNA extraction from 10-20 mg frozen tissue or 2×10^6 cells pellet was performed at Biorepository Core (BioRC) at Children's Hospital of Philadelphia (CHOP). Briefly, tissue was lysed using a Qiagen TissueLyser II (Qiagen, USA) set at 2x30 sec at 18Hz using 5 mm steel beads. Qiagen AllPrep DNA/RNA/miRNA Universal kit including a CHCl₃ extraction was utilized according to manufacturer's protocol. DNA and RNA quantity and quality was assessed by PerkinElmer DropletQuant UV-VIS spectrophotometer (PerkinElmer, USA) and an Agilent 4200 TapeStation (Agilent, USA) for RINe and DINe (RNA Integrity Number equivalent and DNA Integrity Number equivalent). Library preparation and sequencing was performed by the NantHealth sequencing center. Briefly, DNA sequencing libraries were prepared for tumor and matched-normal DNA using the KAPA Hyper prep kit (Roche, USA); tumor RNA-Seq libraries were prepared using KAPA Stranded RNA-Seq with RiboErase kit. Whole genome sequencing (WGS) was performed at an average depth of coverage of 60X for tumor samples and 30X for germline. RNA samples were sequenced to an average of 200M reads. All samples were sequenced on the Illumina HiSeq platform (X/400) (Illumina, San Diego, USA) with 2 x 150bp read length. For the cell line sequencing, samples labelled with "CL-adh" correspond to the adherent FBS cell lines and those labelled "CL-susp" are the "S" serum free lines.

Variant calling and copy number alteration detection. The somatic variant and copy number variation detection workflow was setup using CWL (Common Workflow Language) on CAVATICA. The workflow uses BWA-MEM

v0.7.17¹⁰ to align reads to the GRCh38 reference and SAMBLASTER v0.1.24 to mark duplicate reads, extract discordant/split reads¹¹, and sort the final BAM file. Base Quality Score Recalibration was applied using a model derived from known SNPs and InDels of HapMap, 1000 Genomes, dbSNP138, and Mills Gold Standard Calls databases. GATK4 v4.0.3.0 HaplotypeCaller was used to generate germline gVCF files, merge BAMs, and convert to CRAM as for both germline and tumor samples. Strelka2 v2.9.3 was applied on the aligned tumor-normal pairs to call point somatic mutations and short indels detection¹², Control-FREEC v8.70 was used to detect copy number alterations (CNAs)¹², and MANTA v1.4.0 was used for large structural variant detection.¹³ The single nucleotide variants and indels were then annotated by SnpEff v4.3t and Variant-Effect-Predictor v93.^{14,15} Only select mismatch repair (*MSH2*, *MSH6*, *PMS2*, *POLE*) and glioma-associated (*H3F3A*, *TP53*, *ATRX*, *BRAF*, *IDH1*, *NF1*) gene mutations that ‘PASSED’ Strelka2 filters and had predicted protein damaging effects were used for further analysis. For CNAs, both the Wilcoxon test and Kolmogorov-Smirnov test were performed and events < 10kb in length with p-value > 0.01 were filtered out.

Matched normal blood DNA was screened for rare (ExAC MAF <0.001) damaging mutations and focal deletions in a select panel of mismatch repair deficiency hereditary predisposition genes (*MSH2*, *MSH6*, *POLE*, *MLH1* and *PMS2*). Only those determined to be Pathogenic or likely Pathogenic by InterVar¹⁶ or previously reported¹⁷ were used for further analysis.

Tumor mutation burden analysis. To obtain somatic variants in the coding region, only somatic variants overlapping a consensus exome region (https://github.com/AstraZeneca-NGS/reference_data) were used. The total base pair length of the exome bed was calculated to be 159697302 bp, which was then used to calculate the Tumor Mutation Burden (TMB) per sample as: (Total variants in coding region/length of exome bed (bp)*1000000).

RNA expression quantification. Sequencing data generation and read quality control checks were performed by the NantHealth sequencing center. RNAseq reads were aligned to hg38 reference and gene isoforms quantified using the Toil workflow (STAR v2.61d, RSEM v1.3.1).¹⁸ FPKM (Fragments Per Kilobase of transcript per Million) and TPM (Transcripts Per Million) values were generated. FPKM values were uploaded to PedcBioPortal and we used the TPM values for visualizing the RNAseq data for all the CBTTC samples.

Cell line - primary tumor comparison

Expression comparison

Primary tumor samples and matched cell line RNAseq expression data were filtered to retain genes that are expressed (> 1 TPM). We used 589 patient tumors as a reference set: 99 Ependymoma, 87 High-grade glioma/astrocytoma (WHO grade III/IV), 269 Low-grade glioma/astrocytoma (WHO grade I/II), and 134 Medulloblastoma tumors. We identified the 5000 most variable genes in pediatric tumors, then further restricted the analysis by filtering to genes expressed in both our primary and cell lines samples. This set of 3203 genes was log2 transformed for the reference set, cell lines, and primary tissue samples and pairwise spearman correlation was performed among disease type, cell lines, and their corresponding primary tissues.

Somatic Mutational Signature Analysis

The deconstructSigs R package v1.8.0¹⁹ was used to determine sample-level trinucleotide mutational matrices for all non-silent somatic mutations. Cosine similarities were then calculated for each of the 30 COSMIC signatures using the “genome” normalization mode for BSgenome.Hsapiens.UCSC.hg38.

RESULTS

The CBTTC cohort of pHGG primary tumors represent the spectrum of disease.

The clinical co-variables, genomics and biospecimens of the pHGG set in this study are shown in Table 1, Table S1 and Figure 1. The cohort includes 81 pHGG and *H3.3* mutant PNET primary tumors with both WGS and RNA-seq from PedcBioPortal from 70 participants. An additional two cases (7316-1746 and 7316-599) with established cell lines and one case with proteomic data (7316-37) were included in the cohort. Therefore, the final set includes 73 participants representing 87 collection events from diagnosis and or progression/relapse. Tumors were from participants with a median age of 9 years old at diagnosis, with 97% of our cohort less than 18 years old at diagnosis. The cohort was balanced by sex as 55% of participants were female. The majority (60% of the tumors) were from initial or diagnostic specimens and nearly half (46%) were from a hemispheric location. There were two cases (7316-913, 7316-24) of secondary malignant glioma from patients treated with prior craniospinal radiation for medulloblastoma. Analysis of OncoKB somatic mutations and copy number alterations of a selected set of recurrently mutated pHGG genes were of an expected and representative distribution with 47% *TP53*, 36% *H3.3*, 24% *ATRX* and 7% *BRAF* V600E variants (Table S2 and Figure 1A).

As evident from the Oncoprint (Figure 1A) and as analyzed in PedcBioPortal, we were able to identify previously known co-occurring and mutually exclusive pHGG mutations. These include mutually exclusive *H3.3* G34 and K27M mutations¹ and co-occurring mutations of *ATRX* with *H3.3* G34R²⁰ or *NFI*²¹. In this study, however, we also found that tumors with high confidence *PolE* mutations²² and ultra-hypermutation, also had significant co-occurrence of *ATRX* mutations (Bonferroni adj p value 0.013).

CBTTC patient-derived pHGG biospecimens and resources are highly annotated and molecularly characterized.

pHGG cell lines

The CBTTC biorepository had 37 pHGG tumor tissues stored in freezing media that were dissociated and cultured with four different culturing conditions, resulting in over 80 lines. At least one culture grew from 23/37 (62%) dissociation events from 23/73 (31%) patients in our cohort (Figure 1B). Information including prior patient therapy, culture and growing conditions including orthotopic xenografts, doubling times and validation status are described in Table 2 and Table S3. A subset of the cell lines from patients was sequenced by WGS and RNA-seq by the CBTTC

or targeted Sanger sequencing where primary tumor variants could be identified (Figures 1B and 2 and Table S2). Of the 23 unique patient lines, pHGG driver mutations found in patient tumors validated in 13 derived cell lines, did not validate in four, and six pairs did not harbor known HGG mutations. For the 7316-445 cell line there was absent ATRX protein expression of the tumor on the pHGG TMA (not shown) and in the cell line by Western blot (Figure 3H). The 7316-2189 participant had a family history of childhood brain cancer and clinical diagnosis of Turcot Syndrome on the pathology report (Table S1). The 7316-2189 primary tumor and cell line both had low *PMS2* expression by FPKM on RNA sequencing and a previously described germline *PMS2* mutation.¹⁷ The cell line panel represents the spectrum of pHGG genomics with eight unique patient cell lines with *H3.3* mutations (35%), six with *TP53* mutations (26%), one with a *BRAF* V600E mutation and one with a *KRAS* Q61H mutation. It is noteworthy that all cell lines matched their corresponding primary tumor identity by STR profiling, and also clustered with the cohort of 87 High-grade glioma/astrocytoma (WHO grade III/IV) by expression profiling (Figure 2A). Further studies will determine whether the cell lines that did not validate by sequencing represent non-tumor tissue or are sub-clones of the primary tumors.

Somatic mutations in cancer genomes may be caused by infidelity of the DNA replication machinery, exogenous or endogenous mutagen exposures, enzymatic modification of DNA, or defective DNA repair.²³ To further characterize our set, we compared previously reported somatic mutational signatures of the cell lines to their parental tumors (Fig 2B and Table S5).²⁴ All cell lines displayed the somatic mutational Signature 1 corresponding to spontaneous deamination of 5-methylcytosine (5mC), which is found in most cancer samples. Additional mutational signatures in the cell lines and parental tumors include those of homologous recombination deficiency (HRD) (Signature 3 in 7316-1769), prior alkylator therapy (TMZ) (Signature 11 in 7316-1746 and 7316-3058) and a double nucleotide substitution signature previously reported in breast cancer (BR) and medulloblastoma (MB) (Signature 8 in 7316-1763 and 7316-195). One of the most prevalent signatures were those for mismatch repair (MMR) deficiency (7316-2189) as described further below.

Additional CBTTTC pHGG Resources

In addition to the cell lines, for each of the tumors in the CBTTTC there are additional banked biospecimens including tumor tissue, tumor in freezing media, blood, plasma, CSF and both tumor and blood derived nucleic acids (Table S1). Of the pHGG cohort in this study, 36 patient tumors are also available on a tissue microarray (TMA)

(Figure 1B), along with an additional 40 pHGG and control tissues. This valuable resource will enable researchers to examine the tumor microenvironment, discover cell surface immunotherapy target proteins or perform validation studies of the corresponding proteomic dataset. Finally, to facilitate integrative studies, most of the tumors in the pHGG set have corresponding redacted operative reports, pathology and radiology reports along with the relevant MRI images and histology slides (Figure 1B and Table S4).

Use-case examples demonstrate the potential value of integrated resources to study pHGG

Resources to study hyper-mutation in pHGG

Pediatric high grade gliomas are one of the most common tumors in individuals with constitutional mismatch repair deficiency (CMMRD).²⁵ They have germline loss of function of a mismatch repair gene (including *PMS2*, *MSH2*, *MLH1* or *MSH6*) and frequently acquire secondary somatic *POLE* or *POLD* mutations leading to ultra-hypermutant genomes with a high tumor mutational burden (TMB) > 100 mut/Mb.^{17,22} It is these patients whose tumors have an exceptional clinical response to immune checkpoint inhibition²⁶ and require close tumor surveillance screening.²⁷ Individuals with germline *POLE* mutations often acquire secondary MMR somatic mutations and are hyper-mutant with 10-100 mut/Mb.^{17,22} In our panel of pHGG, six patients (eight tumors) harbored germline mismatch repair mutations and hyper-mutation (Figure 1A) and one patient's tumor is hyper-mutant without an identified germline variant (7316-2307). Four (7316-515 / 2085, 7316-2640, 7316-2189, 7316-212) had germline loss of function *PMS2* or *MSH6* mutations with high confidence somatic *POLE* mutations (Tables S2 and S6).²² As predicted, these tumors were ultra-hypermutant with a TMB > 100 mut/Mb and had a somatic mutational Signature 15 (Figure 2B and Table S5) indicative of defective DNA mismatch repair.²³ One tumor (7316-2980) had a germline *PolE* mutation and secondary *MSH2* mutation and hyper-mutation (28 mut/Mb). Finally, three tumors (7316-2594/3058 and 7316-2756) were from two participants with heterozygous germline *MSH2* mutations (Lynch syndrome). Typically, individuals with Lynch syndrome do not develop cancer until adulthood. Additionally, the tumors from patient PT_JNEV57VK (7316-2594 / 7316-3058) were hyper-mutant. It is possible there were other genetic factors that contributed to glioma tumorigenesis at a young age, and therapeutic factors (i.e. radiation or alkylator therapy) that promoted tumor hyper-mutation.

Three of the hyper-mutant tumors were generated into cell lines (7316-2189, 7316-212 and 7316-3058). Interestingly, we defined the 7316-2189 tumor as ultra-hypermutant (TMB = 327 Mut/Mb), but its matched cell line

was defined as hypermutant (TMB = 14.05 Mut/Mb). To further investigate, we ran somatic mutational signature analysis and found that the 7316-2189 tumor harbored a predominant signature 15 (cosine similarity = 0.91), supporting defective mismatch repair (MMR) in this tumor (Figure 2B). The predominant signature in the 7316-2189 matched cell line was signature 26 (cosine similarity = 0.91), an alternative trinucleotide context and signature of defective MMR, suggesting that even though the cell line is not ultra hypermutant, it still retains MMR deficiency.²³

Availability of a H3.3 G34R mutant pHGG cell line

The development of preclinical cell and murine models of H3.3 K27M mutant midline glioma has significantly advanced the understanding of this histone biology in pHGG and also led to biomarker based clinical trials.³ However, the H3.3 G34R mutation is less common, occurring in 7% of pHGG and 16.2% of hemispheric tumors.¹ Since there are fewer of these tumors, the models are also scarce, hindering discovery efforts for this subset of patients. In our pHGG set, there were two pHGG and two PNETs with a H3.3 G34R mutation, and as expected, were from adolescents with hemispheric tumors (Fig 1A). We were able to generate and characterize the 7316-158 H3.3 G34R line and examine additional resources to study this unique subset of pHGG. The resources include the 7316-158 MRI imaging (Figure 3A), diagnostic H&Es (Figure 3B) and immunohistochemistry slides. In addition, this tumor is on the pHGG TMA and shows protein loss of ATRX staining (Figure 3C). There are additional variants of interest as demonstrated on the tumor Circos plot (Figure 3D). The 7316-158 cell line (Figure 3E) was validated for the *H3.3* G34R mutation (Figure 3F) and absent ATRX protein (Figure 3H), and provides a resource for high throughput drug or genetic testing (Figure 3G, S1). Finally, the cell line from the matched recurrent specimen (7316-5317, Table S1) also has a validated *H3.3* G34R mutation. While the primary tumor sequence will be released in the upcoming updated PBTA2 release, the 7317-5317 cell line is currently available for distribution by the CBTTTC.

DISCUSSION

Pediatric high grade gliomas remain incurable, emphasizing the need for collaborative efforts to openly share data and biospecimens to advance the care for children and adolescents with this rare disease. For example, integration of international pHGG genomic datasets in PedcBioPortal from the CBTTTC (this study), the Herby Trial, Pacific Neuro-Oncology (PNO) 003 clinical trial and International HGG consortium results in over 1500 cases of pHGG and diffuse intrinsic pontine glioma (DIPG).^{1,28,29} These datasets are expected to increase, lending statistical power to

analysis of subsets of pHGG to advance discoveries and collaborations. For example, the second release of data for the CBTTC/PBTA is expected in 2019 and will include additional paired diagnosis and relapse specimens. Moreover, because the PedcBioPortal platform integrates with other non-brain tumor pediatric and adult cancer genomic datasets, the statistical power of discovery is further augmented. The same concept applies to pHGG models including cellular cultures, patient derived xenografts or murine models.³⁰ Each has their unique advantages and limitations, but integration is essential to drive the field forward and necessary for cross-validation studies.

A unique aspect to the CBTTC is the prospective nature of the data collection and the open availability of data and biospecimens for follow up validation or additional discovery efforts. The CBTTC expects that the data and reagents generated from CBTTC specimens are returned to the scientific community as it is recognized that there is greater knowledge that can be learned from collaborative integrative analysis of tumors within a set. Finally, the need to share data and work collaboratively is not only scientifically rational, but is also mandated by the patients and parents who have supported this effort through donation of specimens, data and philanthropy.

This is the first report that focuses on the pHGG data and biospecimens that are available from the CBTTC and PBTA. The two use-cases describe patient cohorts that comprise subtypes of pHGG. We highlight the hyper-mutant pHGG cases and also *H3.3* G34R 7316-158 cell line, which is one of the first published available lines of its kind. Additional subsets include 1) specimens from multiple events which could evaluate resistance or response to therapy (n=11 patients), 2) secondary malignant glioma (n=3) and 3) analysis of tumor with recurrent mutations such as *NFI* or *ATRX*. Additional analyses of the set could include evaluation of the noncoding genome, structural variant analyses and interrogation of germline variation. There are also likely unique opportunities for neuro-radiologists and computational biologists to examine imaging characteristics of these highly characterized tumors.

There are several future initiatives that will enhance the existing pHGG data set and future CBTTC / PBTA studies. The CBTTC clinical data subcommittee recently completed a large data review and bioinformatics effort to provide clinical outcome data, including survival statistics for the CBTTC cohort to be available on PedcBioPortal. There are several current and prospective partnerships with the CBTTC to advance research and therapy for children with brain tumors. For example, a cohort tumors presented in this manuscript is included in the study of multi-omic single cell analyses as part of the NIH Cancer Moonshot Human Tumor Atlas Network (HTAN) and also Project HOPE. In addition, the CBTTC will continue its strong partnership with the Pacific Neuro-Oncology Consortium (PNOC) which is a multi-institution clinical trials network that facilitates rapid translation between basic, translational

and clinical scientists to rapidly advance treatments for children with malignant brain tumors, including pediatric high-grade glioma.

ACKNOWLEDGEMENTS

Clare Choi and Tasso Karras for technical support, Dan Martinez from the CHOP Pathology Core, Martha H.

Williams, Tiffany Smith and Katie Boucher for assistance with cell line generation

AUTHOR GROUPS & CONSORTIA

CBTTC Principal investigators and Co-Investigators, by institution

- 1) Children's Hospital of Philadelphia
- 2) Seattle Children's
- 3) UPMC Children's Hospital of Pittsburgh
- 4) Ann & Robert H. Lurie Children's Hospital of Chicago
- 5) Benioff Children's Hospital (UCSF)
- 6) Stanford University/Lucile Packard Children's Hospital
- 7) Meyer Children's Hospital Florence Italy
- 8) Weill Cornell Medicine Pediatric Brain and Spine Center
- 9) Children's National Health System
- 10) Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center
- 11) Wake Forest Baptist Health
- 12) University of California Santa Cruz – Treehouse Childhood Cancer Initiative
- 13) The Beijing Tiantan Hospital Neurosurgery Center (Beijing, China)
- 14) Genebank (Beijing Genomics Institute – Shenzhen, China)
- 15) Dayton Children's Hospital
- 16) The Hudson Institute of Medical Research (Melbourne, Australia)

CBTTC Foundation Partners

Alan Stallings Fund, Alex Munoz Foundation, Andrew Noten Hudson Foundation, At Least Kids Foundation, Avery Lubrecht Foundation, BethAnn Telford, TeamBT, Brain Tumor Avengers, Brendan Bovard Fund for Brain Tumor Research, Bryce Hansen Bridge of Hope Fund, Charles and Pat Genuardi, Chester County Community Foundation, Children's Brain Tumor Foundation and the Licensing and Merchandiser's Association, Christopher Brandle Joy of Life Foundation, David and Deborah Calvaresi, Derrick and Lauren Roamelle, Dragon Master, Foundation, Eaise Family Foundation, Inc., Grayson Saves Foundation, Hanna Duffy Foundation, James and Nancy Minnick, Joseph T. Lentz Pediatric Brain Cancer Research Fund, Kayla's Hope for Kids Fund, Kyle Daniel Kerpan Foundation, Lauren's First and Goal, Miriam's Kids Research Foundation, Naya Foundation, Pearce Q. Foundation, Inc., PLGA Foundation, Smiles for Jake Foundation, Stanley's Dream, Suzanne Gilligan – Luke Forward, Swifty Foundation, The Christopher Court Foundation, The CJR Memorial Foundation, The Kortney Rose Foundation, The Lilabeau Foundation, The Matthew Renk Foundation, The Timothy Pauxtis Foundation, Thea's Star of Hope, Vs Cancer Foundation, Why Not Me? Foundation, Wylie's Day Foundation

REFERENCES

1. Mackay A, Burford A, Carvalho D, et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. *Cancer Cell* 2017;32:520-37 e5.
2. Salloum R, McConechy MK, Mikael LG, et al. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. *Acta Neuropathol Commun* 2017;5:78.
3. Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. *Nat Med* 2015;21:827.
4. Jones C, Karajannis MA, Jones DTW, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro Oncol* 2017;19:153-61.
5. Felmeiser AS, Masino AJ, Rivera TJ, Resnick AC, Pennington JW. The biorepository portal toolkit: an honest brokered, modular service oriented software tool set for biospecimen-driven translational research. *BMC Genomics* 2016;17 Suppl 4:434.
6. Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep* 2017;7:16878.
7. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401-4.
8. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol* 2017;2017.
9. Sturm D, Orr BA, Toprak UH, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell* 2016;164:1060-72.
10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754-60.
11. Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. *Bioinformatics* 2014;30:2503-5.
12. Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. *Nat Methods* 2018;15:591-4.
13. Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* 2016;32:1220-2.
14. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome Biol* 2016;17:122.
15. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w¹¹¹⁸; iso-2; iso-3. *Fly (Austin)* 2012;6:80-92.
16. Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. *Am J Hum Genet* 2017;100:267-80.
17. Shlien A, Campbell BB, de Borja R, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermuted cancers. *Nat Genet* 2015;47:257-62.
18. Forsyth G. Anatomy of the National Health Service. *Med Care* 1971;9:1-3.
19. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome Biol* 2016;17:31.
20. Korshunov A, Capper D, Reuss D, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. *Acta Neuropathol* 2016;131:137-46.
21. D'Angelo F, Ceccarelli M, Tala, et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. *Nat Med* 2019;25:176-87.
22. Campbell BB, Light N, Fabrizio D, et al. Comprehensive Analysis of Hypermethylation in Human Cancer. *Cell* 2017;171:1042-56 e10.
23. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415-21.
24. Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational processes in human somatic cells. *Nat Genet* 2015;47:1402-7.
25. Wimmer K, Kratz CP, Vasen HF, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). *J Med Genet* 2014;51:355-65.
26. Bouffet E, Larouche V, Campbell BB, et al. Immune Checkpoint Inhibition for Hypermutable Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *J Clin Oncol* 2016;34:2206-11.

27. Tabori U, Hansford JR, Achatz MI, et al. Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. *Clin Cancer Res* 2017;23:e32-e7.
28. Mackay A, Burford A, Molinari V, et al. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. *Cancer Cell* 2018;33:829-42 e5.
29. Mueller S, Jain P, Liang WS, et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. *Int J Cancer* 2019.
30. Brabetz S, Leary SES, Grobner SN, et al. A biobank of patient-derived pediatric brain tumor models. *Nat Med* 2018;24:1752-61.

	#	%
DEMOGRAPHICS, n=73		
CLINICAL EVENT		
initial	44	60 %
recc./progressive	20	27 %
both	5	7 %
SMN	3	4 %
unknown	1	1 %
LOCATION		
midline	37	51 %
hemispheric	34	46 %
unknown	2	3 %
SEX		
female	40	55 %
male	33	45 %
AGE AT DIAGNOSIS	median	range
	9 yrs	0.2-26
GENOMICS, n=70		
TP53	33	47 %
H3.3	25	36 %
ATRX	17	24 %
NF1	19	27 %
BRAF V600E	5	7 %
IDH1	3	4 %
gMMR	6	8 %
RESOURCES, n=73		
WGS/RNAseq	70	96 %
tumor proteomics	21	29 %
operative reports	66	90 %
radiology reports	28	38 %
radiology images	29	40 %
pathology reports	63	86 %
histology images	62	85 %
TMA	36	49 %
cell line	23	31 %

Table 1. Summary of CBTTC pHGG cohort of the Pediatric Brain Tumor Atlas 1.




Figure 1. The CBTTC PBT1 cohort and oncoprint. A. Integrated Oncoprint of the 73 participants in the complete pHGG cohort, with a corresponding key on the right. The demographic data such as event, age at diagnosis, sex and location were downloaded from CBTTC. Availability of WGS/RNAseq and tumor proteomics (red denotes both initial and recurrence) and select somatic pHGG genes (*TP53*, *H3F3A*, *ATRX*, *NF1*, *BRAF*, *IDH1*, *POLE*, *MSH2*, *MSH6*) as annotated by OncoKB were downloaded from PedcBioPortal or KF-DRC. Germline variants in *MSH2*, *MSH6*, *POLE* and *PMS2* and mutational burden were analyzed locally in CAVATICA. The bar graph of age and mutational on the oncoprint are approximate from Table S1 and S5 values. **B. Oncoprint of resources** available for the pHGG set with a descriptive key on the right. Availability of operative, radiology and pathology reports and imaging was downloaded from the KF-DRC manifest. Availability of pHGG FFPE samples on the TMA, cell line availability and sequencing were determined locally. Abbreviations: dx.: diagnosis; recc.: recurrence; NGS = next generation sequencing.

CLINICAL EVENT ID	KIDS FIRST ID	RESEARCH SUBJECT ID	EVENT AGE	SEX	DIAGNOSIS	EVENT	PRIOR TREATMENT	LOCATION	CELL LINE VALIDATION	CELL LINE TYPE, DOUBLING TIME
7316-24	PT_TGQY3X3W	C22878	15	F	HGG	SMN	XRT/chemo	Cerebellum	WGS + IDH1 V187I	A ^E (7d), S (>7d)
7316-85	PT_3AWKWWEV	C28290	2	M	HGG	Initial	None	Temporal Lobe	BRAF V600E	A ^E (7d), S (4d)
7316-158	PT_9BZETM0M	C36285	17	M	PNET	Initial	None	Frontal Lobe	H3F3A G34R	A ^E (3d)
7316-161	PT_Z4BF2NSB	C34809	16	M	HGG	Initial	None	Temporal Lobe		A ^E (6d)
7316-195	PT_Y5KY6KN9	C56826	9	M	HGG	Initial	None	Cerebellum	WGS + H3F3A K27M	A ^E (3d), S (est. >7d)
7316-212	PT_FH0TJ5P2	C60393	18	F	HGG	Recurrence	XRT TMZ, CCNU	Frontal Lobe		A ^f (3d)
7316-339	PT_MQYPS0W1	C70848	11	F	HGG	Initial	None	Temporal Lobe		A ^f (4d)
7316-388	PT_4XB3YTJM	C340710	5	F	HGG	Initial	None	Thalamus	H3F3A K27M	A ^E (2d)
7316-440	PT_KEQ53KRH	C107010	9	F	HGG	Initial	None	Thalamus	TP53 S94*	A ^E (est. 3d)
7316-445	PT_89XRZBSG	C94956	18	M	HGG	Initial	None	Temporal Lobe	CCA+ /ATRX-	A ^E (6d)
7316-599		C89052	1	F	HGG	Initial	None	Thalamus	H3F3A K27M	A ^E (3d)
7316-870	PT_P5HHJJPH	C116727	10	F	HGG	Progressive*	None	Hemispheric; ≥ 2 lobes		A ^E (>7d)
7316-913	PT_4347ZBEX	C216603	21	F	HGG	SMN	XRT/chemo	Temporal Lobe	WGS	A ^f (est. 4d), S (4d)
7316-1102	PT_5BWZA0NT	C292125	12	F	PNET	Initial	None	Ventricles	H3F3A K27M	A ^f (est. 4d)
7316-1746	PT_C2D4JXS1	C337143	6	F	HGG	Initial	TMZ	Cerebellum	KRAS Q61H	A ^E (6d), S (est. 6d)
7316-1763	PT_Z4PJA6KT	C377856	10	F	HGG	Initial	None	Thalamus	H3F3A K27M	S (3d)
7316-1769	PT_JSFBMK5V	C88806	17	M	HGG	Progressive	XRT TMZ, BEV, IRN	Midline	WGS + H3F3A K27M	S (4d)
7316-1956	PT_P2NGYMG5	C597288	12	F	HGG	Initial	None	Cerebellum		A ^E (est. >7d)
7316-2140	PT_QDGVJKE0	C466170	19	M	HGG	Progressive	XRT	Frontal Lobe		A ^f (>7d)
7316-2151	PT_HNZNZ635	C801468	6	M	HGG	Progressive*	None	Thalamus		A ^f
7316-2176	PT_VAJN5QP8	C624225	16	F	HGG	Initial	None	Midline		A ^f (3d)
7316-2189	PT_VTM2STE3	C641691	9	F	HGG	Progressive	Nivolumab	Hemispheric; ≥ 2 lobes	Low PMS2	A ^f (est. >7d)
7316-3058	PT_JNEV57VK	C714384	8	M	HGG	Progressive	XRT TMZ, BEV	Thalamus	H3F3A K27M, ATRX R2197C	A ^E (6d), S (3d)

Table 2. pHGG cell line table. Summary of established pHGG glioma patient derived cell lines. The clinical event ID is also called the “outside event ID” and is denoted by 7316-XXXX. It represents the base name of the cell line and the clinical event from which the line was established. The KidsFirst ID is the participant ID and has the prefix “PT_”. The Research ID is the CBTTTC ID and starts with a “C”. Event age represents the age of the participant at the time of the event. Event designates whether the specimen was collected as an initial sample, at the time of progression or definitive surgery, at recurrence or was a second malignant neoplasm. The location summarizes the location of the tumor. The cell line validation column summarizes the gene and/or method of cell line validation. The cell line type is a list of the best line per sample designated as A (for adherent), S for suspension lines grown in serum free conditions, “f” for a line grown in fetal bovine serum, or “E” for an adherent line grown on an extracellular matrix in serum free conditions. The doubling times were determined by one of the three described methods. Details of the cell lines are found in Table S3.




Figure 2. Parental primary tumor and cell line comparisons. A. Gene expression correlations of pHGG cell lines, parental tumors and brain tumors in the Pediatric Brain Tumor Atlas Set clusters the pHGG cell lines, parental primary tumors (n=9) and High-grade glioma (WHO grade III/IV) tumors (n=87). B. Mutational signatures of the pHGG cell lines (n=10) with corresponding primary tumor (n=9) WGS. “F” is Adherent-FBS. “S” is suspension, serum-free. Type refers to mutational signature nomenclature (COSMIC v2). TMB is the coding tumor mutational burden per Mb. 5mC is a deamination of 5-methylcytosine to thymine signature. HRD is homologous recombination defect associated signature. MMR is defective DNA mismatch repair associated signature. BR and MB are abbreviations for breast cancer and medulloblastoma, respectively. TMZ is a temozolomide signature.




Figure 3. Integrated resources from participant PT_9BZETMOM (C36285) and the corresponding primary tumor (7316-158). **A.** Coronal MRI imaging demonstrates the pre-operative right frontal lobe tumor. **B.** Diagnostic H&E of the 7316-158 primary tumor. **C.** ATRX Immunohistochemistry of the 7316-158 tumor on the pHGG TMA shows absence of ATRX staining in the tumor cells (blue), but positive (brown) staining in cells of the microenvironment. **D.** Circos plot of the WGS of the 7316-158 primary tumor showing mutations (outer ring), copy number variation (middle ring) and structural variants (inner circle). **E.** Light microscopy of the 7316-158 cell line. **F.** Chromatogram of cell line DNA sequencing demonstrating the 7316-158 cell line H3.3 G34R mutation. **G.** Dose response curves of the 7316-158 (H3.3 G34R), 7316-3058 (H3.3 K27M) and 7316-388 (H3.3 K27M) cell lines treated with the Wee1 inhibitor AZD1775. **H.** ATRX Western Blot demonstrating loss of ATRX protein in the 7316-158 and control cell lines.